EGF and non-small cell lung carcinoma: Given that EGF activates AMPK to drive Skp2-mediated ubiquitination and activation of Akt, we next examined whether the AMPK-Skp2-Akt axis contributes to the resistance to EGFR targeting therapy in non-small cell lung cancer cells (NSCLC).